Surrozen (NASDAQ:SRZN) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Surrozen (NASDAQ:SRZN) in a research report report published on Thursday, MarketBeat reports. The firm issued an overweight rating and a $40.00 price target on the stock.

A number of other brokerages have also weighed in on SRZN. Wall Street Zen raised Surrozen to a “sell” rating in a research report on Friday, November 28th. Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Surrozen Trading Down 4.3%

SRZN stock traded down $1.15 during trading on Thursday, reaching $25.78. 14,469 shares of the stock were exchanged, compared to its average volume of 123,224. The firm’s 50 day moving average is $21.80 and its 200 day moving average is $16.18. The firm has a market cap of $220.93 million, a P/E ratio of -1.15 and a beta of 0.58. Surrozen has a twelve month low of $5.90 and a twelve month high of $27.96.

Insider Activity at Surrozen

In other news, major shareholder Tcg Crossover Gp Ii, Llc acquired 17,763 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was purchased at an average price of $23.57 per share, for a total transaction of $418,673.91. Following the purchase, the insider owned 650,567 shares in the company, valued at approximately $15,333,864.19. This represents a 2.81% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Group Gp Lp Column III bought 30,884 shares of the company’s stock in a transaction on Friday, December 5th. The shares were purchased at an average cost of $19.54 per share, for a total transaction of $603,473.36. Following the transaction, the insider owned 981,890 shares in the company, valued at approximately $19,186,130.60. This represents a 3.25% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 231,713 shares of company stock valued at $4,635,485 over the last ninety days. Corporate insiders own 45.18% of the company’s stock.

Hedge Funds Weigh In On Surrozen

Several institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. lifted its holdings in Surrozen by 50.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares during the period. Citadel Advisors LLC increased its position in shares of Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after purchasing an additional 3,424 shares during the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Surrozen during the 4th quarter valued at $99,000. Schonfeld Strategic Advisors LLC raised its stake in shares of Surrozen by 8.1% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 74,645 shares of the company’s stock worth $1,687,000 after purchasing an additional 5,621 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after buying an additional 5,702 shares during the last quarter. 66.57% of the stock is owned by institutional investors.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.